REGN Maintained by HSBC -- Price Target Raised to $920

gurufocus.com · 2026-09-10

On October 3, 2023, HSBC maintained a 'Buy' rating for Regeneron Pharmaceuticals (REGN). The firm has raised the price target to $920 from the previous target o

Read the full story at gurufocus.com →